UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Rev. 1450

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

2292 7590 07/22/2008 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747 EXAMINER

KOSSON, ROSANNE

ART UNIT PAPER NUMBER

DATE MAILED: 07/22/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,360	08/18/2006	Jim Jannes	0641-0278PUS1	8842

TITLE OF INVENTION: MUTATION ASSOCIATED WITH A DECREASED RATE OF RELEASE OF T-PA

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$720	\$300	\$0	\$1020	10/22/2008

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION NO THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and I/2 the ISSUE FFE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where

appropriate. All further indicated unless corrects maintenance fee notifica	ed below or directed of	ng the Patent, advance on herwise in Block 1, by (rders and notification of a a) specifying a new corre	maintenance fees v spondence address	vill be ; and/o	mailed to the current r (b) indicating a sepa	correspondence address a rate "FEE ADDRESS" fo
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)				Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, mus have its own certificate of mailing or transmission.			
PO BOX 747	7590 07/22 ART KOLASCH CH, VA 22040-0747	& BIRCH	I he Stat add tran	Cereby certify that the es Postal Service veressed to the Mai ismitted to the USP	rtificate us Fec(vith sul I Stop TO (57	e of Mailing or Transa s) Transmittal is being ficient postage for firs ISSUE FEE address 1) 273-2885, on the da	nission deposited with the United class mail in an envelope above, or being facsimile tte indicated below.
							(Depositor's name)
			_				(Signature)
							(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR		ATTO	RNEY DOCKET NO.	CONFIRMATION NO.
10/563,360	08/18/2006		Jim Jannes		0	641-0278PUS1	8842
			ASED RATE OF RELEAS				T
APPLN, TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSU	E FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$720	\$300	\$0 1		\$1020	10/22/2008
EXAM		ART UNIT	CLASS-SUBCLASS	J			
KOSSON,		1652	435-006000 2. For printing on the p				
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.86). Change of correspondence address (or Change of Correspondence Address (or Change of Correspondence Address form PTOSB#122) attached. Tee Address' indication (or "Fee Address' Indication form PTOSB#47 (Rev 03-02 or more recent) attached. Use of a Customer Number is required.			(1) the aames of up to 3 registered patent attorneys 1 (2) the name of a single firm (having as a member a registered attorney or agents old the names of up to 1 listed, no name will be printed.				
PLEASE NOTE: Uni recordation as set fort (A) NAME OF ASSI	less an assignee is ident h in 37 CFR 3.11. Comj 3NEE	ified below, no assignee pletion of this form is NO	THE PATENT (print or ty data will appear on the p IT a substitute for filing an (B) RESIDENCE: (CITY	natent. If an assign assignment. and STATE OR (COUNT	TRY)	cument has been filed for
Please check the appropr	iate assignee category or	categories (will not be p			•		
4a. The following fee(s) Issue Fee Publication Fee (N Advance Order -	o small entity discount j		b. Payment of Fee(s): (Plea A check is enclosed. Payment by credit can The Director is hereby overpayment, to Depo	rd. Form PTO-2038	is atta	iched.	thown above) Ticiency, or credit any a extra copy of this form).
	s SMALL ENTITY state	as. See 37 CFR 1.27.	☐ b. Applicant is no lon				
NOTE: The Issue Fee an interest as shown by the	d Publication Fee (if req records of the United Sta	uired) will not be accepte tes Patent and Trademark	d from anyone other than to Office.	the applicant; a reg	istered.	attorney or agent; or th	e assignee or other party ir
Authorized Signature				Date			
Typed or printed name				Registration !			
This collection of inform an application. Confiden submitting the completes this form and/or suggests Box 1450, Alexandria, V Alexandria, Virginia 223	ation is required by 37 C tiality is governed by 35 d application form to the ons for reducing this bu (irginia 22313-1450. DC 13-1450.	CFR 1.311. The informatic U.S.C. 122 and 37 CFR USPTO. Time will vary rden, should be sent to the ONOT SEND FEES OR	on is required to obtain or 1.14. This collection is es depending upon the indi- e Chief Information Offic COMPLETED FORMS T	retain a benefit by timated to take 12 vidual case. Any co er, U.S. Patent and O THIS ADDRES:	the pub minuter omment Trader S. SEN	lic which is to file (and s to complete, includin ts on the amount of tir nark Office, U.S. Depa D TO: Commissioner I	by the USPTO to process g gathering, preparing, and the you require to complete atment of Commerce, P.O. for Patents, P.O. Box 1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

ss: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/563,360	08/18/2006	Jim Jannes	0641-0278PUS1	8842	
2292 7	590 07/22/2008		EXAMINER		
BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747			KOSSON, ROSANNE		
			ART UNIT PAPER NUMB		
			1652		

DATE MAILED: 07/22/2008

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Notice of Allowability

Application No.	Applicant(s)	
10/563,360	JANNES ET AL.	
Examiner	Art Unit	
Posanna Kosson	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address-All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant See 37 CFR 1.313 and MPEP 1308.

- This communication is responsive to an amendment filed on May 22, 2008.
- The allowed claim(s) is/are 1,2,6,9 and 131.
- 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a)

 All b)

 Some* c)

 None of the:
 - 1. \(\subseteq \text{ Certified copies of the priority documents have been received.} \)
 - 2. Certified copies of the priority documents have been received in Application No. _____
 - Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 - * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDOMMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

- A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
- 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date _____
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- 1. Notice of References Cited (PTO-892)
- 2. Notice of Draftperson's Patent Drawing Review (PTO-948)
- Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date
- Examiner's Comment Regarding Requirement for Deposit of Biological Material
- 5. Notice of Informal Patent Application
- Interview Summary (PTO-413), Paper No./Mail Date .
- 7. X Examiner's Amendment/Comment
- 8. X Examiner's Statement of Reasons for Allowance
- 9. Other .

Application/Control Number: 10/563,360

Art Unit: 1652

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows.

The specification is amended as follows.

The following paragraph is inserted after the title.

This application is the U.S. national phase of International Application No. PCT/AU04/00905, filed on July 2, 2004, which claims priority to Australian Application No. 2003-903412, filed on July 4, 2003.

The claims are amended as follows.

1. (currently amended) A method of identifying a subject predisposed to ischemic stroke, wherein said method comprises:

determining the presence of a mutation in the subject that reduces the release rate <u>from endothelial cells into the circulation</u> of tissue plasminogen activator <u>(t-PA).</u> [[and]] wherein said mutation is a cytosine to thymine mutation at position -7351 of the upstream region of the <u>human</u> tissue plasminogen <u>activator</u> locus, <u>which is position 2228 of SEQ ID NO:1</u>.

10-11. (canceled)

13. (canceled)

17. (canceled)

35. (canceled)

38. (canceled)

40. (canceled)

49-50. (canceled)

115. (canceled)

Application/Control Number: 10/563,360

Art Unit: 1652

132-134. (canceled)

Authorization for this Examiner's Amendment was given by telephone by Applicants' agent, Mr. Thomas Siepmann, on July 7, 2008.

2. The following is an examiner's statement of reasons for allowance. The prior art does not teach or suggest the mutation recited in the claims or a method of using this mutation to identify subjects at increased risk for stroke. As previously discussed, Bulens et al. disclose several regions located upstream of the human t-PA gene that are necessary for normal t-PA activity and whose effect can be measured in a CAT assay, in which 9.8 kb of the upstream region of the human t-PA gene are cloned into an expression vector containing the CAT gene and a thymidine kinase promoter. Individual and multiple deletions of various elements in this upstream region are made, and the expression of CAT in all the constructs is compared. One of these regions, an everted element known as ER8, is located between nucleotide positions -7325 and -7535 (see p. 7170 and 7171, left col.), a region that includes the mutation found by Applicants at position -7351. The deletion of this element was found to decrease the expression of CAT two-fold relative to the control (no deletions). One of ordinary skill in the art at the time of the invention would have known that when a polynucleotide region that functions in the activity, presence or expression of a particular protein is deleted, that deletion is likely to result in decreased protein activity or amount when measured in an in vitro assay. One of ordinary skill in the art at the time of the invention also would have known that subjects having a mutation in the genomic area upstream of the t-PA gene would produce less t-PA, or have less t-PA in their blood, and, as a result, would be more likely to suffer from thrombotic disorders such as heart attack and stroke. Further, one of ordinary skill in the art would have known the importance of identifying these individuals at risk for heart attack and stroke as a prophylactic measure. But, the prior art does not disclose Applicants' mutation in the upstream region of the

Page 4

Application/Control Number: 10/563,360

Art Unit: 1652

human t-PA gene.

3. Any comments considered necessary by applicant must be submitted no later than the

payment of the issue fee and, to avoid processing delays, should preferably accompany the

issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons

for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Rosanne Kosson whose telephone number is (571)272-2923. The

examiner can normally be reached on Monday-Friday, 8:30-6:00, alternate Mondays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Nashaat Nashed can be reached on 571-272-0934. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you

would like assistance from a USPTO Customer Service Representative or access to the

automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Rosanne Kosson

Examiner, Art Unit 1652

rk/2008-07-01

/Rebecca E. Prouty/ Primary Examiner.

Art Unit 1652

Application/Control Number: 10/563,360 Page 5

Art Unit: 1652

Abstract

The present invention relates to a method of identifying a subject predisposed to ischemic stroke. The method includes the step of identifying a mutation in the subject that reduces the release rate of tissue plasminogen activator.